CART 358
Alternative Names: CART-358Latest Information Update: 28 Jun 2022
At a glance
- Originator Multitude Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 17 Jun 2022 CART 358 is available for licensing as of 17 Jun 2022. https://www.multitudetherapeutics.info/partnering
- 17 Jun 2022 Preclinical trials in Liver cancer in USA (Parenteral) (Multitude Therapeutics pipeline, June 2022)